Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy - Wikidata - awgldk - TriplyDB

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

http://www.wikidata.org/entity/Q26795555

about

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer Recent developments in the use of immunotherapy in non-small cell lung cancer.Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer.The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.A case report of tongue metastasis from lung squamous cell carcinoma and literature review.Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma.

P2860

Q26778500-888BF3D5-254E-4514-9A7A-64FEF50A8E03 Q38826419-901E572A-95DE-44F5-A849-AACCC1BDFB45 Q38872183-D780A3EE-7A63-4CDB-82BB-C629C51A902E Q38981789-AA46BAE1-57B7-466A-B855-514B58FF4339 Q39039088-5A3C281B-03FE-4593-BF7A-53588A3CFE31 Q42341991-0A21A2B6-DAC9-44E6-B52A-2662AA45E754 Q47152410-9B7F38B7-999C-43CF-A1EF-03210F3BAA79 Q47556226-226DE047-F960-4936-B25E-68C6D8032096 Q53692985-7DDE1B50-2E41-4BCB-99F0-A7A36CC72976

P2860

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

http://www.wikidata.org/entity/Q26795555

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Treating patients with ALK-pos ...... idence and management strategy

@ast

Treating patients with ALK-pos ...... idence and management strategy

@en

Treating patients with ALK-pos ...... idence and management strategy

@nl

type

label

Treating patients with ALK-pos ...... idence and management strategy

@ast

Treating patients with ALK-pos ...... idence and management strategy

@en

Treating patients with ALK-pos ...... idence and management strategy

@nl

prefLabel

Treating patients with ALK-pos ...... idence and management strategy

@ast

Treating patients with ALK-pos ...... idence and management strategy

@en

Treating patients with ALK-pos ...... idence and management strategy

@nl

P1433

Q26795555-89431C9B-6B10-44C9-9B9B-F1D14555AC35

P1476

Q26795555-3BBE51F5-53C5-4B19-888F-A888C629F230

P2093

Q26795555-11625B6A-C515-4A69-A800-794192E09930

Q26795555-579D8ED0-B0BE-4B6E-BCBF-3D3BB9516F1B

P2860

Q26795555-0675BF5B-2DBC-4684-BC80-BB860B5A01A8

Q26795555-069AB178-070E-4604-9A21-C111879A9DFB

Q26795555-0B036835-E4A0-42C3-AB3B-343EDE12764C

Q26795555-0BD050FC-AF4E-436D-8968-CDA552E182C4

Q26795555-0CEDDF09-1095-455A-A3EB-B077AC5460A3

Q26795555-0E6C17CC-12A6-49AF-B9A2-8AD9A24479A4

Q26795555-0FB4C73B-D287-4F1D-92A5-E8B887DA3E03

Q26795555-1344FE65-D33E-46B1-8EC7-8A46C604B8E3

Q26795555-15711757-12F3-47C0-ABC3-3FB86F98227D

Q26795555-1616D066-368A-4CAC-911A-BF04F54F3072

P304

Q26795555-407D9D26-CC95-481C-B9BE-03FAC4CCCB85

P31

Q26795555-FCADECFE-FE0E-4F3A-9FAC-387A6A751006

P356

Q26795555-26B93BA2-E2C5-46DE-A82A-27F6E2C1CFA0

P407

Q26795555-28D98341-587C-4C66-8916-1E1A63428C8E

P433

Q26795555-DD558E71-91CB-4B25-A00E-AD16C86AB40D

P478

Q26795555-30AEC442-BB1E-4FBD-A58C-A47F6DB8E237

P50

Q26795555-544304F6-88E7-40E1-BEFA-517DEF775FEA

Q26795555-5E85AB3A-3240-4B20-A1B6-C7226B8DDFC1

P577

Q26795555-5BB01FDE-4294-400C-A393-2B2174AAE562

P5875

Q26795555-AE8EA9F5-C4F4-4FFB-8C21-0BC96D0D5E92

P698

Q26795555-1492CF01-8260-4582-9EED-F22FCAEB4CE4

P932

Q26795555-925BD5C8-6DFD-4174-9679-1CCCEE546A15

P356

1758834015590593

P1433

Therapeutic advances in medical oncology

P1476

Treating patients with ALK-pos ...... idence and management strategy

@en

P2093

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

Jin-Yuan Shih

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

P304

274-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834015590593

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

James Chih-Hsin Yang

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281368216

http://www.w3.org/2001/XMLSchema#string

P698

26327925

http://www.w3.org/2001/XMLSchema#string

P932

4543853

http://www.w3.org/2001/XMLSchema#string